Patient-Reported Outcomes as an Indicator of Disease Transitions in Heart Failure

Active, not recruitingOBSERVATIONAL
Enrollment

3,640

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Heart Failure
Interventions
OTHER

Provider Focus

The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.

OTHER

Patient Interview

A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.

OTHER

PROs/Clinical Data Integration

A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.

Trial Locations (1)

84143

Intermountain Heart Institute, Murray

All Listed Sponsors
lead

Intermountain Health Care, Inc.

OTHER

NCT04264845 - Patient-Reported Outcomes as an Indicator of Disease Transitions in Heart Failure | Biotech Hunter | Biotech Hunter